Overcoming STING-Driven Immunosuppression with a Bifunctional STING Agonist/PD-L1 Inhibitor for Enhanced Antitumor...

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Stimulator of interferon gene (STING) pathway activation is a promising cancer immunotherapy strategy.
• STING agonist monotherapy faces challenges like inconsistent efficacy and drug resistance, partly due to programmed death ligand 1 (PD-L1) upregulation.
• Overcoming PD-L1 upregulation is crucial for enhancing STING-based cancer treatments.

Purpose of the Study:

• To develop a molecular conjugation strategy to mitigate STING-induced PD-L1 upregulation.
• To identify a novel therapeutic candidate that activates the STING pathway and inhibits PD-1/PD-L1 interactions.
• To evaluate the synergistic antitumor efficacy and safety of the developed candidate.

Main Methods:

• Molecular conjugation strategy to create a dual-action molecule.
• Identification and characterization of the lead candidate, SMU-3k.
• In vivo efficacy studies in the MC38 murine colon cancer model.

Main Results:

• SMU-3k effectively activates the STING pathway and blocks PD-1/PD-L1 interaction.
• SMU-3k demonstrated robust and synergistic inhibition of tumor growth in the MC38 model.
• No significant immune-related adverse effects were observed with SMU-3k treatment.

Conclusions:

• The developed molecular conjugation strategy successfully mitigates STING-driven PD-L1 upregulation.
• SMU-3k represents a promising therapeutic candidate for enhancing cancer immunotherapy.
• This approach provides a strong foundation for preclinical development of combination immunotherapies.